China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in a Phase I/IIa clinical study being carried out in the United States for its Aurora A inhibitor JAB-2485. The initial indication for the study is general advanced solid tumors, marking a significant step in the development of this innovative therapy.
Clinical Trial Details
JAB-2485 is an in-house discovery by Jacobio Pharma and represents a highly selective small-molecule Aurora A inhibitor. It is a potential global first-in-class candidate, although it is the third Aurora A inhibitor to enter clinical stages in the United States. The Phase I/IIa study will be conducted independently by Jacobio’s clinical team, focusing on assessing the safety, tolerability, and preliminary efficacy of JAB-2485 in patients with advanced solid tumors.
Preclinical Data and Therapeutic Potential
Preclinical data indicate that JAB-2485 has the potential to produce strong anti-tumor activity while being highly selective for Aurora A at both biochemical and cellular levels. The molecule’s inhibitory activity against Aurora A is reportedly 1,000 times higher than for Aurora B. This high selectivity suggests that JAB-2485 may offer significant therapeutic advantages, particularly in patients with small-cell lung cancer and triple-negative breast cancer.
Furthermore, relevant studies have shown that Aurora A inhibitors, in combination with SHP2 inhibitors, may help resolve acquired drug resistance to KRAS G12C inhibitors. Additionally, synergistic anti-tumor effects are expected when JAB-2485 is combined with BET inhibitors, further expanding its potential therapeutic applications.
Future Outlook
The initiation of the Phase I/IIa clinical study for JAB-2485 highlights Jacobio Pharma’s commitment to advancing innovative cancer therapies. With its demonstrated preclinical efficacy and selectivity, JAB-2485 has the potential to address significant unmet needs in the treatment of advanced solid tumors. Jacobio’s ongoing clinical development efforts underscore its dedication to improving patient outcomes in oncology.-Fineline Info & Tech
